[Chronic myeloid leukemia and tyrosine kinase inhibitors].
BACKGROUND
Chronic myeloid leukemia is a myeloproliferative disorder clinically characterised by a triphasic course: after a chronic phase over a median time of 4 years, patients developed an accelerated phase, then a blastic phase, resulting in the patient's death with 3 to 6 months.


OBJECTIVE
During the last past years, progress have been made in the understanding of the molecular mechanism responsible of leukemic growth. This has also provided support for a therapeutic improvement with the appearance of treatment such as tyrosine kinase inhibitors which specifically target the oncoprotein inside the leukemic cells.


CONCLUSIONS
These treatments, such as STI571 or Glivec, are at present in clinical trials, and could be the medicines for the future. Thus, chronic myeloid leukemia is also a model for the development of the new therapeutic drugs.
Mahon
F X
FX
Laboratoire de greffe de moelle, université Victor-Segalen, UMR CNRS 5540, 146, rue Léo-Saignat, 33076 Bordeaux, France. Francois-Xavier.Mahon@umr5540.u-bordeaux2.fr
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D002986:Clinical Trials as Topic; D003582:Cytogenetics; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl